Biotechnology company Regeneron Pharmaceuticals is buying 23andMe for $256 million, two months after the genetic testing ...

Regeneron is buying 23andMe for $256M in bankruptcy, gaining access to DNA data from 15 million users to aid drug research.

Regeneron Pharmaceuticals is acquiring the assets of 23andMe for $256 million, excluding its Lemonaid Health business, as the ...

Regeneron Pharmaceuticals Inc. was the successful bidder for 23andme Holding Co.’s personal genome service, total health and ...

Regeneron Pharmaceuticals Inc. (NASDAQ:REGN) announced Monday that it has secured the winning bid in the bankruptcy auction ...

On Monday, Regeneron Pharmaceuticals announced that it would acquire most of 23andMe's assets for $256 million. According to ...

The deal would put the DNA data of millions of customers in the hands of a pharmaceutical company, which hopes to supercharge ...

Regeneron Pharmaceuticals said it would acquire 23andMe, which filed for bankruptcy in March and would continue to offer ...

Dow Jones Top Company Headlines at 5 PM ET: Regeneron to Buy 23andMe Out of Bankruptcy for $256 Million | Jamie ... The move raises privacy concerns as the drugmaker takes control of the genetic data ...

Regeneron Pharmaceuticals has promised to comply with 23andMe's existing privacy polices while also using data to fuel drug ...